China Health Group Inc. launched the Real World Study with top medical institutions in China on anti-dementia clinical 10,000 patients. The Study is aimed at improving the standardized treatment of Alzheimer's disease through clinical research by linking hundreds of grassroots hospitals with Internet technology, and involving many tertiary hospitals in China such as the Sixth Hospital of Peking University, the First Hospital of Peking University, and the General Hospital of the People's Liberation Army. The two Studies launched this time are led by Prof. Wang Huali and Prof. Mao Zhiqi respectively, with a total of 10,000 cases planned to be completed within 2 years. Alzheimer's Disease International (ADI) said that a new report found that an estimated 41 million dementia cases worldwide have not been diagnosed and that new treatment breakthroughs could lead to an impending "Demand Tsunami" for diagnoses that could crush unprepared health care systems around the world and more than 100 global Alzheimer's disease and dementia associations worldwide. The Management believes that the Group's Clinical Research Center for prevention and treatment of dementia and stroke has participated in the 70% of recent market clinical research of drugs in the field of dementia in China. This clinical research and the promotion of new clinical research drugs under big data will have an important impact on the long-term revenue of the Group. China Health Group Inc. is a leading enterprise that, driven by the three cores of the Real World Study, Real World Data and Artificial Intelligence, provides three major services for life sciences, precision digital medical "research-based specialty" CHGmyD services, Real World Study CHGRWS services and the Scientific research product promotion service of reconstructing the trillion dollar drug promotion market CRSO services. The Group focuses on the two century epidemic diseases of brain science and allergy, and constructs five specialty brands: baimin Kangmin, Xixin spirit, Xien prevention and treatment of stroke mania, Yuejie smoking addiction and ALS. Shareholders and potential investors are advised to exercise caution when dealing in the shares of the Company and, in case of doubt, to seek independent advice from professionals or financial advisers.